Clinical Study
Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma
Table 1
Baseline characteristics.
| | | Prospective group () | Retrospective group () | Study population () |
| | Gender | | | | | Males | 3 (43%) | 5 (50%) | 8 (47%) | | Females | 4 (57%) | 5 (50%) | 9 (53%) | | Age | | | | | Median (range) | 63 (20–74) | 68 (46–80) | 64 (20–80) | | ECOG performance status (3 missing data items) | | | | | 0 | 3 (43%) | 2 (29%) | 5 (36%) | | 1 | 3 (43%) | 5 (71%) | 8 (57%) | | 2 | 1 (14%) | — | 1 (7%) | | Stage | | | | | Locally advanced | 1 (14%) | 3 (30%) | 4 (24%) | | Metastatic | 6 (86%) | 7 (70%) | 13 (76%) | | Grading (1 missing data item) | | | | | G1 | — | — | — | | G2 | 3 (43%) | 4 (44%) | 7 (44%) | | G3 | 4 (57%) | 5 (56%) | 9 (56%) | | Previous surgery | | | | | Yes | 5 (71%) | 9 (90%) | 14 (82%) | | Previous chemotherapy | | | | | None | — | 5 (50%) | 5 (29%) | | Only adjuvant | — | 2 (20%) | 2 (12%) | | Advanced disease | 7 (100%) | 3 (30%) | 10 (59%) |
|
|
